Lymphoma
Kite’s Tecartus® CAR T-cell Therapy Demonstrates 78% Complete Response Rate and 90% Overall Response Rate in Largest Real-World Evidence Analysis for Relapsed/Refractory Mantle Cell Lymphoma Kite, a Gilead Company (Nasdaq:…
Read MoreLymphoma
Breast Cancer
Trodelvy® Continues to Show Durable Overall Survival Advantage in Pre-Treated HR+/HER2- Metastatic Breast Cancer Gilead Sciences, Inc. (Nasdaq: GILD) today announced longer-term overall survival (OS) results from the Phase 3…
Datopotamab Deruxtecan Combinations Showed Encouraging TumorResponses in Patients with Advanced Non-Small Cell Lung Cancer inTROPION-Lung02 Phase 1b trial
Datopotamab Deruxtecan Combinations Showed Encouraging TumorResponses in Patients with Advanced Non-Small Cell Lung Cancer inTROPION-Lung02 Phase 1b trial Updated results from the TROPION-Lung02phase 1b trial showed that with additional enrollment…
Catalent Expands OneBio® Suite for Integrated Development, Manufacturing and Supply Across Biologic Modalities
Catalent Expands OneBio® Suite for Integrated Development, Manufacturing and Supply Across Biologic Modalities Catalent, the leader in enabling the development and supply of better treatments for patients worldwide, today announced that…
WHO announces winners of the 4th Health for All Film Festival
WHO announces winners of the 4th Health for All Film Festival The World Health Organization has announced the official selection of this year’s winning films at its 4th Annual Health for…
Andexxa Phase IV trial stopped early after achieving pre-specified criteria on haemostatic efficacy versus usual care
Andexxa Phase IV trial stopped early after achieving pre-specified criteria on haemostatic efficacy versus usual care ANNEXA-I, a post-marketing Phase IV trial to assess the efficacy and safety of Andexxa (andexanet alfa)…
AMGEN PRESENTS NEW LUMAKRAS® (SOTORASIB) CODEBREAK 200 CNS DATA AT ASCO 2023
AMGEN PRESENTS NEW LUMAKRAS® (SOTORASIB) CODEBREAK 200 CNS DATA AT ASCO 2023 Amgen (NASDAQ:AMGN) today announced the presentation of new data from the CodeBreaK clinical trial program, the most comprehensive global…
Teva Presents Real-World
Teva Presents Real-World Data for AUSTEDO® (deutetrabenazine) Tablets with 4-Week Patient Titration Kit at Psych Congress Elevate 2023 Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and…
Sanofi launches 2023 global Employee Stock Purchase Plan
Sanofi launches 2023 global Employee Stock Purchase Plan Sanofi launches Action 2023, its global employee shareholder plan, open to around 86,000 employees in 56 countries. The program builds on…
Phase 3 Studies of Pfizer’s Novel Antibiotic Combination Offer New Treatment Hope for Patients with Multidrug-Resistant Infections and Limited Treatment Options
Phase 3 Studies of Pfizer’s Novel Antibiotic Combination Offer New Treatment Hope for Patients with Multidrug-Resistant Infections and Limited Treatment Options Pfizer Inc. (NYSE: PFE) today announced positive results from…
Novartis receives European approval for Cosentyx® as first and only IL-17A inhibitor for hidradenitis suppurativa
Novartis receives European approval for Cosentyx® as first and only IL-17A inhibitor for hidradenitis suppurativa Novartis announced today that the European Commission (EC) has approved Cosentyx® (secukinumab) for use in adults…
FDA Approves
FDA Approves LYNPARZA® (olaparib) Plus Abiraterone and Prednisone or Prednisolone for Treatment of Adult Patients With BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer (mCRPC) AstraZeneca and Merck (NYSE: MRK),known as MSD outside…